source
- Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference. Central among the buz…
- Triplet immunotherapy improves survival in HER2‑positive gastric cancer, suggesting broader immune activationNew data from a study of HER2‑positive gastric cancer patients evaluated a triplet immunotherapy regimen. The analysis compared the combination against standard approaches and focused on overall su…